In a patient cohort of 392, 97.7% of samples were determined to be valid and un-falsified.
In 2022, Bicycle Health initiated research on the UDS process it developed for telehealth settings. The objective of the study was to determine the rate of falsification of UDS testing among patients with OUD in active treatment with buprenorphine via telehealth.
In September of 2023, the results of that study were published in the Journal of Substance Use and Addiction Treatment.
This is the first study published on the falsification rates of urine drug screenings administered via telehealth OUD treatment programs.
Download the White Paper
"In 2021, we saw over 75,000 opioid-related deaths in the U.S. — yet less than 10% of people accessed treatment, usually due to stigma, lack of accessibility, and the cost of treatment. This descriptive review is a major validation of Bicycle Health’s innovative telehealth model as we work to bring effective OUD treatment to patients across the country, and ultimately help more people live fulfilling lives free from opioid addiction."